These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27035329)

  • 1. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity.
    Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH
    J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB; Lookingland KJ; Bédard PJ; Huff RM
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1248-56. PubMed ID: 15980060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.
    Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S
    ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta.
    Zingales V; Torrisi SA; Leggio GM; Bucolo C; Drago F; Salomone S
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33799860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.
    Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML
    Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol.
    Paul NM; Taylor M; Kumar R; Deschamps JR; Luedtke RR; Newman AH
    J Med Chem; 2008 Oct; 51(19):6095-109. PubMed ID: 18774793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands.
    Peng X; Wang Q; Mishra Y; Xu J; Reichert DE; Malik M; Taylor M; Luedtke RR; Mach RH
    Bioorg Med Chem Lett; 2015 Feb; 25(3):519-23. PubMed ID: 25556097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTPγS assays.
    Zhen J; Antonio T; Ali S; Neve KA; Dutta AK; Reith ME
    J Neurosci Methods; 2015 Jun; 248():7-15. PubMed ID: 25840364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palmitoylation on the carboxyl terminus tail is required for the selective regulation of dopamine D2 versus D3 receptors.
    Zhang X; Le HT; Zhang X; Zheng M; Choi BG; Kim KM
    Biochim Biophys Acta; 2016 Sep; 1858(9):2152-2162. PubMed ID: 27349735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes.
    Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J
    J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatic linker variations in novel dopamine D
    Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.